Morgan Stanley analyst Jeffrey Hung raised the firm’s price target on Neurocrine to $170 from $160 and keeps an Overweight rating on the shares. The firm is in line with consensus on Ingrezza net product sales, but believes Ingrezza sales for the quarter will be less impactful to Neurocrine shares given investor focus on upcoming NBI-1117568 Phase 2 topline results due in Q3, the analyst tells investors in a Biotechnology group preview.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NBIX:
- Neurocrine price target raised to $173 from $169 at JPMorgan
- Jefferies says Neurocrine, Alkermes not seeing Sublocade-like impact on Medicaid
- Neurocrine announces FDA accepted two NDAs
- Neurocrine presented CAHtalyst Phase 3 studies at ENDO 2024
- Neurocrine announces CAHtalyst Pediatric Phase 3 study met primary endpoint